Crinetics Reports Strong PALSONIFY Launch & Positive Phase 2 Atumelnant Data for CAH

summarizeSummary

Crinetics Pharmaceuticals announced strong preliminary Q4 2025 net product revenue for PALSONIFY and positive topline Phase 2 results for atumelnant in congenital adrenal hyperplasia, demonstrating successful commercial execution and pipeline advancement.

check_boxKey Events

• Strong PALSONIFY Launch

  Preliminary Q4 2025 net product revenue exceeded $5.0 million for PALSONIFY, the company's recently approved drug for acromegaly. Key commercial metrics include over 200 enrollment forms and more than 125 unique prescribers, indicating robust initial uptake.

• Positive Atumelnant Phase 2 Results

  Topline data from the Phase 2 TouCAHn trial for atumelnant in congenital adrenal hyperplasia (CAH) showed rapid and sustained reduction in androstenedione (A4) levels. Seven out of eight patients in Cohort 4 successfully reduced glucocorticoid (GC) doses to physiologic levels while maintaining lower A4.

• Favorable Safety Profile Maintained

  Atumelnant continued to demonstrate a well-tolerated safety profile in both Cohort 4 and the Open-Label Extension of the Phase 2 study, with no serious adverse events or treatment-related severe adverse events, including no hepatic transaminase adverse events.

auto_awesomeAnalysis

This 8-K filing provides a highly positive update for Crinetics Pharmaceuticals, highlighting successful commercial execution and significant pipeline progress. The preliminary Q4 2025 net product revenue of over $5.0 million for PALSONIFY, a recently approved drug, indicates a strong initial launch with encouraging metrics such as high enrollment and prescriber adoption. This suggests a positive trajectory for the company's first commercial product. Furthermore, the positive topline results from the Phase 2 TouCAHn trial for atumelnant in congenital adrenal hyperplasia (CAH) are a major de-risking event for this key pipeline asset. The data demonstrated effective reduction of androstenedione (A4) levels while allowing for a reduction in glucocorticoid (GC) doses to physiologic levels, a critical unmet need in CAH treatment. The sustained efficacy and favorable safety profile, with no serious adverse events or hepatic transaminase issues, build strong confidence as atumelnant progresses towards Phase 3. These combined updates reinforce Crinetics' potential to redefine the standard of care in endocrine diseases and provide substantial positive momentum for the company.